SRSF2 and renal carcinoma: At present, a few studies have reported that hsa-miR-183-5p can promote canceration by targeting SRSF2 in renal cancer [58], miR-335 could inhibit the proliferation and invasion of clear renal cells through suppressing Bcl-w [59], hsa-miR-365b-3p is poorly associated with ccRCC patient survival [60] and hsa-miR-9-5p is associated with the development and risk of renal cancer recurrence [61].